Corient Private Wealth LLC Buys 87,468 Shares of DexCom, Inc. $DXCM

Corient Private Wealth LLC boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 241.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 123,754 shares of the medical device company’s stock after buying an additional 87,468 shares during the period. Corient Private Wealth LLC’s holdings in DexCom were worth $8,221,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC lifted its position in DexCom by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after acquiring an additional 42,411 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of DexCom by 6.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock valued at $530,897,000 after purchasing an additional 516,526 shares during the last quarter. Norges Bank acquired a new position in shares of DexCom in the fourth quarter valued at approximately $483,356,000. Invesco Ltd. increased its stake in shares of DexCom by 14.8% during the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock worth $352,781,000 after purchasing an additional 686,228 shares during the period. Finally, CIBC Private Wealth Group LLC increased its stake in shares of DexCom by 7.6% during the fourth quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock worth $207,613,000 after purchasing an additional 220,313 shares during the period. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on DXCM shares. Deutsche Bank Aktiengesellschaft started coverage on DexCom in a report on Tuesday. They set a “buy” rating and a $86.00 price target for the company. Citigroup reiterated a “buy” rating and set a $84.00 price objective (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. Robert W. Baird set a $80.00 price objective on DexCom in a research report on Friday, May 1st. Stifel Nicolaus set a $90.00 target price on DexCom and gave the stock a “buy” rating in a report on Friday, June 5th. Finally, Benchmark reissued a “buy” rating on shares of DexCom in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $84.88.

DexCom Stock Up 1.2%

Shares of DXCM opened at $69.73 on Thursday. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The firm’s 50 day moving average is $67.36 and its 200-day moving average is $68.04. The stock has a market capitalization of $26.91 billion, a PE ratio of 29.80, a P/E/G ratio of 1.08 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.32 earnings per share. Equities research analysts forecast that DexCom, Inc. will post 2.58 EPS for the current year.

Insider Transactions at DexCom

In other news, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the sale, the director directly owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the completion of the transaction, the executive vice president owned 100,361 shares in the company, valued at $7,326,353. The trade was a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 46,694 shares of company stock worth $3,343,977. Corporate insiders own 0.28% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.